{{Rsnum
|rsid=17152408
|Gene=ZRANB1
|Chromosome=10
|position=126649007
|Orientation=plus
|GMAF=0.1837
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 2.7 | 29.2 | 68.1
| HCB | 2.9 | 32.1 | 65.0
| JPT | 5.3 | 37.2 | 57.5
| YRI | 2.7 | 38.8 | 58.5
| ASW | 3.5 | 28.1 | 68.4
| CHB | 2.9 | 32.1 | 65.0
| CHD | 4.6 | 24.8 | 70.6
| GIH | 5.9 | 24.8 | 69.3
| LWK | 4.5 | 41.8 | 53.6
| MEX | 3.4 | 31.0 | 65.5
| MKK | 4.5 | 32.7 | 62.8
| TSI | 2.9 | 23.5 | 73.5
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs17152408
|Name_s=
|Gene_s=ZRANB1
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: A, MAF= 0.16, combined P value= 2.38E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470215
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs17152408
|overall_frequency_n=22
|overall_frequency_d=126
|overall_frequency=0.174603
|n_genomes=21
|n_genomes_annotated=0
|n_haplomes=22
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}